Navigation Links
Stallergenes Moves to the Cloud With Veeva CRM
Date:10/11/2011

BARCELONA, Spain, October 11, 2011 /PRNewswire/ --

Leading Specialty Pharmaceutical Company Consolidates Four On-Premise CRM Systems into One

Stallergenes, the world leader in sublingual immunotherapy, has selected Veeva CRM to replace its existing conventional on-premise systems to support its worldwide sales force. Veeva CRM is today's #1 selling cloud-based CRM solution for the global pharmaceutical and biotech industry.

Previously, Stallergenes utilised four different Customer Relationship Management (CRM) systems across 14 countries before selecting Veeva CRM.  Veeva was chosen from a pool of CRM vendors to support Stallergenes growing international operations and new sales force effectiveness initiative. According to the company, Veeva CRM proved to be the most innovative and robust solution, enabling improved customer targeting, increased understanding of customer behaviour and enhanced coordination of data between the field force, medical affairs and marketing teams.


"We needed a system that could support rapid growth across borders," said Cyril Tavier, vice president, international operations at Stallergenes. "Veeva's cloud-based solution is the gold standard in new, innovative technologies, allowing the high level of flexibility and scalability we need to support our expanding operations globally. Veeva is a perfect match for our company, and supports our mission as an industry innovator."

Thierry Grehaigne, vice president, information technologies at Stallergenes added, "We wanted a single, comprehensive CRM solution that would be intuitive and easy to use for all users across regions and that could keep pace with changing technology. Veeva had it all."

Stallergenes will also be rolling out Veeva's leading iPad application, iRep, to users in major European markets. Veeva iRep is the first integrated CLM/CRM application designed specifically for the Apple iPad. Veeva redesigned its CRM application to leverage the many strengths of the iPad and added closed loop marketing functionality to allow seamless alignment of sales and marketing strategies and execution.

"We are very excited about how iRep will revolutionise our customer interactions by bringing us closer to our customers and being able to respond to their specific needs," added Cyril Tavier.  "The integrated CRM and CLM functionality in iRep will allow our teams to tailor marketing and medical messages to micro-segments of the market.  And, we'll have a constant feedback loop between the field force and head office." 

Over the past four years, Veeva Systems has quickly become a leading provider of CRM solutions to the global pharmaceutical industry. Because of its cloud-based platform, Veeva CRM requires no hardware or software to purchase, scale, or maintain. In addition, all Veeva customers benefit from free, automatic upgrades so users are always on the most current version of the software and benefit from the very latest compliance changes and system enhancements.

"Veeva CRM will play a pivotal role in the speed at which we develop our international operations and deliver on our new sales force effectiveness programme," said Cyril Tavier.

"Forward-thinking pharma companies throughout Europe, like Stallergenes, are realising the value in replacing limited, on-premise applications with Veeva's flexible cloud-based enterprise solution," concluded Dan Goldsmith, general manager of Veeva Europe. "We look forward to working closely with the Stallergenes team as their commercial enterprise grows."


About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross turnover to Research & Development and is actively involved in the development of a new therapeutic class, sublingual immunotherapy tablets. In 2010, the company had a turnover of 216 million euros, and more than 500,000 patients were treated with Stallergenes products.

About Veeva CRM

The Veeva CRM suite of applications, comprised of VBioPharma, iRep, VMobile, and VInsights, is the pharmaceutical and biotechnology industry's leading cloud-based CRM solution. In addition, iRep has quickly become the industry's choice for closed loop marketing on the iPad. Only Veeva CRM accommodates the unique needs of multiple commercial teams in a single solution, improving user adoption and sales effectiveness, while reducing cost and complexity. Veeva CRM is now the foundation on which the pharmaceutical industry is adapting its sales and marketing models for the future.

About Veeva Systems

Veeva Systems is the leader in cloud-based solutions for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has over 100 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Founded in 2007, Veeva is a privately held company headquartered in the San Francisco Bay Area, with offices in Philadelphia, Barcelona, Budapest, Paris, Beijing, Shanghai, and Tokyo. For more information, visit http://www.veevasystems.com

Copyright (c) 2011 Veeva Systems. All rights reserved. Veeva and the Veeva logo are registered trademarks of Veeva Systems. Veeva Systems owns other registered and unregistered trademarks. Other names used herein may be trademarks of their respective owners.

Media Contact
Selma Nawaz
European Marketing Director
Veeva Systems
selma.nawaz@veevasystems.com



'/>"/>
SOURCE Veeva Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
2. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
3. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
4. Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
5. STALLERGENES: Persistent Efficacy Demonstrated After a Year on Actair(R) Followed by a Second Treatment-Free Year
6. STALLERGENES: Excellent 1st Half-Year 2010 Performance
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
9. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
10. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
11. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... YORK , December 2, 2016 ... the trading session in red, while the Dow Jones Industrial ... at the close of US markets, which prompted Stock-callers this ... stocks: NuVasive Inc. (NASDAQ: NUVA ), Smith & ... (NASDAQ: NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Technologies, Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer ... given according to organs involved and the types of cancer as ...
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to needy individuals and families from eight different sites throughout Miami-Dade and Broward ... Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual ...
(Date:11/30/2016)... Boston, Massachusetts (PRWEB) , ... November 30, 2016 ... ... is proud to announce that we have been designated as a Cigna Infertility ... meet or exceed rigorous performance standards. , “It’s an honor to be ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... treatment has announced the opening of a new eating disorder treatment center location ... outpatient treatment for adults and adolescents, both males and females ages 10 and ...
(Date:11/30/2016)... ... 2016 , ... The Clinical Data Interchange Standards Consortium (CDISC) ... goes into effect next month. Sponsors whose studies start after December 17, 2016 ... The current FDA Data Standards Catalog specifies the use of CDISC standards: ...
Breaking Medicine News(10 mins):